[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:cytomegaloviral-infection":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":161,"states":165},"Cytomegaloviral Infection",24,20,[8,16,22,28,34,41,48,54,60,66,72,78,84,91,98,104,110,115,122,128,134,141,148,154],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06853184","Study Evaluating the Efficacy and Safety of Artesunate",[12],"Phase 2","RECRUITING","2026-08-26T02:17:04.346841Z","2026-05-29T15:36:40.170841Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT03266640","Virus Specific Cytotoxic T-Lymphocytes (CTLs) for Refractory Cytomegalovirus (CMV)",[12],"2026-08-26T02:16:31.714843Z","2026-05-05T02:47:14.270391Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":26,"content_modified":27},"NCT06066957","Open Label Trial of Oral Letermovir for CMV Prophylaxis in Thoracic Transplant Recipients",[12],"2026-08-26T02:18:26.932189Z","2026-05-05T02:43:28.287048Z",{"nct_id":29,"title":30,"phases":31,"status":13,"updated_at":32,"content_modified":33},"NCT04706923","A Phase 2a Study of IV BCV in Subjects With Adenovirus Infection",[12],"2026-08-03T03:23:28.660374Z","2026-05-05T02:43:27.843415Z",{"nct_id":35,"title":36,"phases":37,"status":13,"updated_at":39,"content_modified":40},"NCT05319353","A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Cytomegalovirus (CMV) Infection in Children and Adolescents Who Have Received a Hematopoietic Stem Cell Transplant (HSCT) or a Solid Organ Transplant (SOT)",[38],"Phase 3","2026-08-26T02:15:22.311223Z","2026-05-05T02:43:27.612294Z",{"nct_id":42,"title":43,"phases":44,"status":13,"updated_at":46,"content_modified":47},"NCT07199465","A Clinical Study of Letermovir (MK-8228) in Children and Adolescents Who Receive a Kidney Transplant (KT) (MK-8228-077)",[45],"Phase 1","2026-08-26T02:19:09.651016Z","2026-05-05T02:35:31.623428Z",{"nct_id":49,"title":50,"phases":51,"status":13,"updated_at":52,"content_modified":53},"NCT05183490","R-MVST Cells for Treatment of Viral Infections",[45],"2026-08-26T02:17:14.343713Z","2026-05-05T02:43:29.726676Z",{"nct_id":55,"title":56,"phases":57,"status":13,"updated_at":58,"content_modified":59},"NCT06407232","Letermovir (Prevymis) for CMV in Kidney and Pancreas Transplant Recipients",[38],"2026-08-26T02:18:11.042248Z","2026-05-05T02:43:28.359980Z",{"nct_id":61,"title":62,"phases":63,"status":13,"updated_at":64,"content_modified":65},"NCT02532452","Third Party Viral Specific T-cells (VSTs)",[12],"2026-08-26T02:19:13.549512Z","2026-05-05T02:43:28.672557Z",{"nct_id":67,"title":68,"phases":69,"status":13,"updated_at":70,"content_modified":71},"NCT05101213","Study Assessing the Feasibility, Safety and Efficacy of Genetically Engineered Glucocorticoid Receptor Knock Out Virus Specific CTL Lines for Viral Infections in Immunosuppressed Cancer Patients",[45],"2026-08-03T03:52:12.406209Z","2026-05-05T02:43:28.347086Z",{"nct_id":73,"title":74,"phases":75,"status":13,"updated_at":76,"content_modified":77},"NCT06926894","R-MVST Cells for Treatment of Viral Infections in Children and Young Adults",[45],"2026-08-26T02:17:53.433613Z","2026-05-05T02:43:27.623199Z",{"nct_id":79,"title":80,"phases":81,"status":13,"updated_at":82,"content_modified":83},"NCT04013802","TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.",[45],"2026-08-26T02:16:09.452956Z","2026-05-05T02:43:27.168885Z",{"nct_id":85,"title":86,"phases":87,"status":13,"updated_at":89,"content_modified":90},"NCT06909110","Viral Specific T-Lymphocytes to Treat Infection With Adenovirus, Cytomegalovirus or Epstein-Barr Virus in Patients With Compromised Immunity",[88],"Phase 1\u002FPhase 2","2026-08-26T02:16:15.345907Z","2026-05-05T02:43:27.099634Z",{"nct_id":92,"title":93,"phases":94,"status":13,"updated_at":96,"content_modified":97},"NCT05626530","Letermovir for Secondary Prophylaxis in Solid Organ Transplant Recipients",[95],"Phase 4","2026-08-26T02:17:42.501124Z","2026-05-05T02:43:28.808139Z",{"nct_id":99,"title":100,"phases":101,"status":13,"updated_at":102,"content_modified":103},"NCT07096453","CMVIG Prophylaxis in Belatacept Conversion Kidney Transplant Recipients",[88],"2026-08-26T02:16:08.402952Z","2026-05-05T02:43:27.595971Z",{"nct_id":105,"title":106,"phases":107,"status":13,"updated_at":108,"content_modified":109},"NCT06522880","Cytomegalovirus (CMV) Transmission and Immune Tracking (TransmIT) Study",[],"2026-08-03T02:43:45.928258Z","2026-05-13T02:55:06.498331Z",{"nct_id":111,"title":112,"phases":113,"status":13,"updated_at":20,"content_modified":114},"NCT05234723","Ganciclovir Resistant\u002FRefractory Cytomegalovirus Infection in SOT Recipients and HSCT Patients",[],"2026-06-16T05:54:08.027520Z",{"nct_id":116,"title":117,"phases":118,"status":13,"updated_at":120,"content_modified":121},"NCT02982902","T Cell Therapy of Opportunistic Cytomegalovirus Infection",[119],"Early Phase 1","2026-08-26T02:16:24.135291Z","2026-05-05T02:43:29.669092Z",{"nct_id":123,"title":124,"phases":125,"status":13,"updated_at":126,"content_modified":127},"NCT06639854","The Use of Cytomegalovirus Cell Mediated Immunity to Optimize the Duration of Letermovir Prophylaxis in Hematopoietic Cell Transplant Recipients",[],"2026-08-26T02:16:28.221034Z","2026-05-05T02:43:29.213137Z",{"nct_id":129,"title":130,"phases":131,"status":13,"updated_at":132,"content_modified":133},"NCT03354728","Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Treating Pediatric Patients With Positive Cytomegalovirus Undergoing Donor Stem Cell Transplant",[88],"2026-08-26T02:17:30.961790Z","2026-05-05T02:43:29.071890Z",{"nct_id":135,"title":136,"phases":137,"status":138,"updated_at":139,"content_modified":140},"NCT07706166","Letermovir for R+ Study",[95],"NOT_YET_RECRUITING","2026-08-26T02:17:28.381459Z","2026-07-19T19:36:05.087065Z",{"nct_id":142,"title":143,"phases":144,"status":145,"updated_at":146,"content_modified":147},"NCT07009548","CytoGam for CMV Infection or Disease in Solid Organ Transplant Recipients",[95],"ENROLLING_BY_INVITATION","2026-08-26T02:18:23.582895Z","2026-06-16T05:54:07.848820Z",{"nct_id":149,"title":150,"phases":151,"status":145,"updated_at":152,"content_modified":153},"NCT06027879","Anti-viral T-cell Therapy by Gamma Capture",[88],"2026-08-26T02:17:35.666428Z","2026-06-16T05:54:08.096276Z",{"nct_id":155,"title":156,"phases":157,"status":158,"updated_at":159,"content_modified":160},"NCT05683457","A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Allogenic Hematopoietic Cell Transplantation (HCT) Participants.",[12],"ACTIVE_NOT_RECRUITING","2026-08-03T03:37:48.267540Z","2026-05-05T02:43:28.820419Z",[162],{"biomarker":4,"count":163,"slug":164},6,"cytomegaloviral-infection",[166,170,173,176,180,184,187,191,194],{"state":167,"count":168,"slug":169},"Texas",7,"texas",{"state":171,"count":163,"slug":172},"Ohio","ohio",{"state":174,"count":163,"slug":175},"Pennsylvania","pennsylvania",{"state":177,"count":178,"slug":179},"California",5,"california",{"state":181,"count":182,"slug":183},"Massachusetts",4,"massachusetts",{"state":185,"count":182,"slug":186},"New York","new-york",{"state":188,"count":189,"slug":190},"Illinois",3,"illinois",{"state":192,"count":189,"slug":193},"Minnesota","minnesota",{"state":195,"count":189,"slug":196},"Wisconsin","wisconsin"]